Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
|Videos|November 4, 2021
Emerging Psychedelic Therapies
Author(s)Alexander Somjen
Here's why psychedelics might be a valuable addition to mental health treatment.
Advertisement
Alexander Somjen discusses the fragmented psychedelic industry, regulatory frameworks, and potential commercial success.
Alexander Somjen is the CEO and Director of
Advertisement
Related to this article
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
2
The New, Impending Adult ADHD Guidelines
3
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
4
Relief Is Not Free: A Case Study of Athlete Cannabis Use
5